Legal aspects of FDA regulatory Compliance: Preparing for an FDA Facility Inspection and Responding to a 483 Letter
May 18, 2020
Webinar
In addition to evaluating data from adverse event reports, the bulk of FDA’s regulatory enforcement comes from its facility inspections and resulting 483 reports. This practical webinar will cover numerous aspects of preparing your drug or medical device establishment for a successful FDA facility inspection and responding to any post-inspection 483 letters. The key to a successful inspection strategy is adequate preparation and implementing the inspection plan before FDA knocks on your door. Attendees will learn:
-
- What to expect during the inspection;
- Strategies for preparing for an inspection;
- What to expect after the inspection;
- Strategies for responding to any deficiencies noted in a 483 report;
- Potential product liability issues stemming from a 483 report.
Recent News
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
- In Memory of Dr. Michael Rinck, Founder, MT Promedt Consulting GmbH
- bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
- Priority Review Granted for PolarityBio’s SkinTE for Treatment of Diabetic Foot Ulcers
- National Institutes of Health Award Inherent Biosciences a Direct-to-Phase II SBIR Grant
- Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
